Glenmark Pharmaceuticals Limited
http://www.glenmarkpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Glenmark Pharmaceuticals Limited
India Q2 Preview: Glenmark, Cipla Emerge Stronger
With the impact of pandemic-prompted disturbances waning, analysts forecast better Q2 numbers for Indian pharma firms, with some including Glenmark and Cipla seen emerging winners. But after doing well in the quarter, Gilead’s licensees might see remdesivir demand tapering somewhat in Q3 post the WHO finding the antiviral ineffective in COVID-19 treatment.
Rivals Challenge Nintedanib In India
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.
Cut-Price Generics Set To Challenge Boehringer’s Nintedanib In India
Glenmark and Sun Pharma introduce nintedanib generics in India at a fraction of the innovator product’s price, vying for a share of the IPF market where pirfenidone currently holds sway.
Coronavirus Update: J&J Pauses COVID-19 Vaccine Trial After Unexplained Illness
J&J becomes the second company to pause a COVID-19 vaccine trial, releasing few details but emphasizing the measure's precautionary nature.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- OTC, Consumer
- Specialty Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Integrace
- Integrace Private Limited
- Ichnos Sciences